HER2 mutation inhibitors

This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds an...

Full description

Saved in:
Bibliographic Details
Main Authors ELLIS, BRYAN DANIEL, NEWHOUSE, BRADLEY JON, BOYS, MARK LAURENCE, PAJK, SPENCER PHILLIP, LAIRD, ELLEN RUTH, GAUDINO, JOHN JOSEPH, HICKEN, ERIK JAMES, LAZZARA, NICHOLAS CHARLES
Format Patent
LanguageChinese
English
Published 16.04.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
Bibliography:Application Number: TW202110123381